Search - tctmd.com

Displaying 21 - 40 of 54

Sort: Relevancy | Date

Presentation TCT 2016

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2016

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Presenter: Deepak L. Bhatt, Christian W. Hamm

October 30, 2016

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White, Philippe Généreux

October 15, 2015

Presentation TCT 2015

Cangrelor II: Perspectives on in Whom to Actually Use It

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor I: Data Essentials From the Champion Trials

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

Presenter: Deepak L. Bhatt, Martin Rose, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Gregg W. Stone

October 13, 2015

Presentation TCT 2015

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Freddy Abnousi

October 13, 2015

Presentation TCT 2015

Intravenous P2Y12 Inhibition: Role for Cangrelor

Presenter: George D. Dangas, Paul A. Gurbel, Robert A. Harrington

October 13, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Deepak L. Bhatt

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Advertisement

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

My Takeaways From TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: Perspectives on in Whom to Actually Use It

Cangrelor I: Data Essentials From the Champion Trials

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Intravenous P2Y12 Inhibition: Role for Cangrelor

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content